



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 04 Apr 2022 (#13)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notices

- **Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office)** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.
 - FMHS contact: cdevries@sun.ac.za
 - Stellenbosch Campus contact lizelk@sun.ac.za.

Link to the training: https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html

Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

Notice of Special Interest

- [NOT-AT-22-004](#) **Notice of Special Interest (NOSI): Dissemination and Implementation Research to Advance Mental, Emotional, and Behavioural Health Preventive Interventions in School Settings.** The purpose of this Notice of Special Interest (NOSI) is to stimulate dissemination and implementation research to support innovative approaches to identifying, understanding, and developing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up and sustainability of evidence-based preventive interventions to support children's mental, emotional, and behavioural (MEB) health in school settings. This NOSI encourages applications which focus on dissemination and implementation research to deliver interventions in the school setting that will promote healthy MEB development and/or prevent MEB disorders. Applications should include a focus on one of the following: (1) primary/universal prevention MEB programs designed to promote healthy MEB development by decreasing risk factors and increasing protective factors to prevent onset of an MEB disorder; or (2) secondary/selective prevention programs designed to support screening and early identification of MEB disorders to slow progression with early intervention. Applications focused on tertiary/indicated

treatment of MEB disorders will be considered non-responsive to this Notice. This notice applies to due dates on or after June 5th, 2022 and subsequent receipt dates through June 5, 2024. Applicants planning to submit an application in response to this NOSI are strongly encouraged to contact and discuss their proposed research/aims with an NIH Program Officer listed on this NOSI well in advance of the grant receipt date.

- [NOT-DK-22-017](#) **Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Epidemiologic Studies of Diabetes Incidence and Severity and Its Potential Association with COVID-19.** NIDDK is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for epidemiologic studies of diabetes incidence and severity and its potential association with coronavirus disease 2019 (COVID-19) and the causative virus SARS-CoV-2. The epidemiologic study in the proposed supplement **does not need to be within the current scope of the active award.** NIDDK intends to make multiple awards based on this urgent competitive revision. The total budget for these epidemiologic studies is \$3 million. Application budgets are limited to the current year direct cost budget, or \$350,000 direct costs (whichever is less), exclusive of consortium FA costs. Applications will be accepted until **1 June 2022, by 5:00 PM local time** of the applicant organization.
- [NOT-ES-22-005](#) **Notice of Special Interest (NOSI): Promoting Health, Safety, and Recovery Training for COVID-19 Essential Workers and their Communities.** The purpose of this supplement is to provide support for successful applicants to develop partnerships with local worker centers and community organizations specifically targeting under served and disadvantaged communities with higher-than-average COVID-19 transmission rates. Applications may be submitted beginning on 4 April 2022 for the Application Due Date on 6 June 2022. Budget requests for applications as an *Administrative Supplement* can exceed the total cost of the parent award. No request can exceed \$400,000 total cost.
- [NOT-HD-22-002](#) **Notice of Special Interest (NOSI) - Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities.** The COVID-19 pandemic continues to be the source of much mortality and morbidity creating and contributing to both physical and mental health issues. Recent data suggest that nearly one million individuals have died from COVID-19 in the United States. However, the impact of the SARS-CoV-2 virus as well as the associated measures to prevent and treat this infection extend well beyond the issue of mortality. Although much needed information regarding the epidemiology, transmission and potential acute treatments including the development of an effective vaccine have been gleaned in unprecedented time, important issues remain to be elucidated including, but not limited to the effect of the virus and its treatment on menstrual health, fertility and the offspring of infected and/or vaccinated parents, the impact of the Delta and Omicron variants and other emerging variants, the occurrence of viral co-infections and the many physical and mental health issues created by the pandemic itself. The purpose of this funding opportunity is to provide an avenue for researchers to pursue funding to conduct research addressing these and other emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. The goal of this NOSI is to not replace or compete with the various COVID-related funding opportunities currently available. Instead, the purpose is to complement them. This notice applies to due dates on or after 5 June 2022 and subsequent receipt dates through 6 June 2024.

Funding Opportunity Announcements (FOA)

1. Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-22-025](#)

Type: R01

Application Due Date: 3 August 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this Funding Opportunity Announcement (FOA) is to support basic research to define cellular and molecular mechanisms within persistent HIV reservoir cells that promote survival and resistance to virus-induced and immune-mediated cell death, and to identify novel therapeutic targets that could sensitize HIV-infected cells to eradication strategies. Applications meeting the following conditions will be considered non-responsive and will not be reviewed:

- Studies focused primarily on improving latency reversal
- Studies focused primarily on enhancing effector cell killing
- Approaches designed to bypass cellular mechanisms for eradication, such as HIV-specific antibodies or immunotoxins

- Applications that do not include primary cells from HIV/SIV-infected hosts
- Applications proposing clinical trials

Budget: Issuing IC and partner components intend to commit an estimated total of \$3,300,000 to fund 3-6 awards in FY23. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Implementation Research to Reduce Noncommunicable Disease (NCD) Burden in Low- and Middle-Income Countries (LMICs) and Tribal Nations During Critical Life Stages and Key Transition Periods (R01 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-22-132](#)

Type: R01

Application Due Date: 27 July 2022 and AIDS date 10 August 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the [Global Alliance for Chronic Diseases](#) (GACD), invite applications for implementation research focused on addressing risk factors for common noncommunicable diseases (NCDs) in [World Bank-defined low- and middle-income countries](#) (LMICs) and American Indian/Alaska Native (AI/AN) Tribal Nation populations in the United States. This Funding Opportunity Announcement (FOA) supports innovative approaches to identifying, understanding, developing, and implementing strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines. In addition, studies to advance dissemination and implementation research methods and measures into application are encouraged. Specifically, this FOA invites applications that propose interventions targeting critical life stages (e.g., infancy, childhood, adolescence, pregnancy, older adults) and key transitions between life stages to reduce health risk and/or enhance positive health and lifestyle behaviors. All applications must be within the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations"). Applications will be accepted from US and World Bank-defined LMIC institutions only. Potential applicants are strongly encouraged to contact NIH IC program staff (listed below) early in the application process to discuss the alignment of their technical proposal with the goals of this FOA, the NIH IC, and the GACD program.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Division for Research Development (DRD)
Stellenbosch Campus
2041 Krotoa Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105